Esperion Therapeutics Inc (ESPR)
1.995
-0.04
(-1.72%)
USD |
NASDAQ |
Nov 04, 16:00
2.01
+0.02
(+0.75%)
After-Hours: 20:00
Esperion Therapeutics Revenue (Quarterly): 73.83M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 73.83M |
| March 31, 2024 | 137.74M |
| December 31, 2023 | 32.25M |
| September 30, 2023 | 33.97M |
| June 30, 2023 | 25.79M |
| March 31, 2023 | 24.33M |
| December 31, 2022 | 18.82M |
| September 30, 2022 | 18.98M |
| June 30, 2022 | 18.84M |
| March 31, 2022 | 18.84M |
| December 31, 2021 | 15.40M |
| Date | Value |
|---|---|
| September 30, 2021 | 14.41M |
| June 30, 2021 | 40.66M |
| March 31, 2021 | 7.978M |
| December 31, 2020 | 9.638M |
| September 30, 2020 | 3.833M |
| June 30, 2020 | 212.24M |
| March 31, 2020 | 1.84M |
| December 31, 2019 | 0.982M |
| September 30, 2019 | 0.981M |
| June 30, 2019 | 0.982M |
| March 31, 2019 | 145.42M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.982M
Minimum
Dec 2019
212.24M
Maximum
Jun 2020
37.39M
Average
18.84M
Median
Jun 2022
Revenue (Quarterly) Benchmarks
| Perspective Therapeutics Inc | -- |
| Nektar Therapeutics | 23.49M |
| Alaunos Therapeutics Inc | 0.004M |
| Oragenics Inc | -- |
| Cocrystal Pharma Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -61.92M |
| Total Expenses (Quarterly) | 71.26M |
| EPS Diluted (Quarterly) | -0.33 |
| Enterprise Value | 471.51M |
| Gross Profit Margin (Quarterly) | 78.86% |
| Profit Margin (Quarterly) | -83.87% |
| Earnings Yield | -43.11% |
| Operating Earnings Yield | 1.65% |
| Normalized Earnings Yield | -28.97 |